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Abstract
Background: Tumor immune-evasion and associated failure of immunotherapy can potentially be overcome by
radiotherapy, which however also has detrimental effects on tumor-infiltrating and circulating lymphocytes (CL). We
therefore established a model to simulate the radiation-dose delivered to CL.
Methods: A MATLAB-model was established to quantify the CL-dose during SBRT of liver metastases by considering the
factors: hepatic blood-flow, −velocity and transition-time of individual hepatic segments, as well as probability-based
recirculation. The effects of intra-hepatic tumor-location and size, fractionation and treatment planning parameters (VMAT,
3DCRT, photon-energy, dose-rate and beam-on-time) were analyzed. A threshold dose ≥0.5Gy was considered inactivating
CL and CL0.5 (%) is the proportion of inactivated CL.
Results: Mean liver dose was mostly influenced by treatment-modality, whereas CL0.5 was mostly influenced by beam-on-
time. 3DCRT and VMAT (10MV-FFF) resulted in lowest CL0.5 values of 16 and 19%. Metastasis location influenced CL0.5, with
a mean of 19% for both apical and basal and 31% for the central location. PTV-volume significantly increased CL0.5 from 27
to 67% (10MV-FFF) and from 31 to 98% (6MV-FFF) for PTV-volumes ranging from 14cm3 to 268cm3.
Conclusion: A simulation-model was established, quantifying the strong effects of treatment-technique, tumor-location and
tumor-volume on dose to CL with potential implications for immune-optimized treatment-planning in the future.
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Background
Despite continuous multidisciplinary efforts, the pro-
spect to transform advanced tumors into a state of
“chronic disease” are still limited. Immunotherapy has
shown encouraging clinical results by enhancing or in-
ducing tumor-specific immune responses [1], however,
tumor immune evasion represents a major challenge of
cancer treatment today [2–4].
Major reasons for immune evasion are the immunosup-
pressive microenvironment of the tumor and insufficient
infiltration of immune competent cells into the tumor
[1, 5–11]. Radiotherapy has been demonstrated to over-
come the immunosuppressive tumor microenvironment
[12] and anecdotal reports suggest that local tumor irradi-
ation may also exert systemic or abscopal anti-tumor
effects by immune-response modification with subsequent
response of non-irradiated tumor metastases [13–22]. Ra-
diation does however also have detrimental effects not
only on tumor infiltrating lymphocytes but also on circu-
lating lymphocytes (CL) in the bloodstream during radio-
therapy, as these cells are particularly radiosensitive [23].
In addition, prolonged lymphopenia during or after the
tumor treatment has been shown to be a prognostic factor
for overall survival in many cancer types and radiotherapy
may be an important factor [24–27]. In this regard, circu-
lating lymphocytes should be treated as a radiosensitive
organ at risk.
Conventional fractionated radiotherapy could have an
increased negative impact compared to hypofractionated
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approaches such as SBRT, because of usually larger irra-
diated volumes and overall treatment times of several
weeks. This might lead to a significantly larger percent-
age of lymphocytes receiving a dose of more than
0.5 Gy, which is considered as a threshold dose for im-
paired lymphocyte function [23, 28]. The use of stereo-
tactic body radiotherapy (SBRT) has increased rapidly in
recent years and changed the field of radiation therapy
in general, as well as outcome for select patients tremen-
dously [29, 30]. Nearly all studies combining radiother-
apy and immunotherapy focus on the use of SBRT with
high ablative doses and a low number of fractions or
even single fraction stereotactic radiosurgery (SRS).
This study aimed to establish a model to quantify the
radiation dose delivered to CL. The proportion of circu-
lating lymphocytes exposed to at least 0.5 Gy (CL0.5)
was used as a surrogate parameter for radiation-induced
immunosuppression. The model was established for
SBRT of intra-hepatic metastases because many cancer
types metastasize into the liver and liver SBRT is well
established in the radiation oncology community. We
analyzed the influence of various SBRT planning and
delivery parameters such as dose rate, beam energy,
treatment time, fractionation and treatment technique
on the immunosuppressive effects of radiotherapy; add-
itionally, the influence of PTV volume and intra-hepatic
tumor location were investigated.
Methods
Model setting
For this in-silico planning study, three virtual liver
metastases, positioned at different intrahepatic locations,
were planned with SBRT of 3 × 15 Gy.
A contrast-enhanced CT scan of the liver was used for
treatment planning. Contouring was performed in the
treatment planning software Eclipse (Varian Medical Sys-
tems). Contours included the whole liver (1195 cm3), the
hepatic segmentation into eight individual segments (I –
VIII), portal vein, hepatic artery, inferior vena cava, aorta,
lungs, spleen and kidneys. Contouring was performed ac-
cording to the normal organ contouring guidelines for Ra-
diation Therapy Oncology Group (RTOG) trials [31].
Three virtual liver metastases with a spherical diameter of
2 cm were delineated with either apical (a), basal (b) or
central (c) location (Fig. 1). A PTV margin of 0.5 cm was
added leading to a spherical diameter of 3 cm and a PTV
volume of 14 cm3. While we kept the lesion size equal for
all tumor locations and treatment modalities for compar-
ability, we generated three additional larger lesions in the
central location to evaluate volume-effects on circulating
lymphocytes. Larger GTV diameters of 4, 5 or 7 cm were
chosen resulting in PTV volumes of 65 cm3, 113 cm3 and
268 cm3, respectively.
Eclipse was used for treatment planning and DVH dose
calculation. A fractionation of 3 × 15 Gy was chosen with
an inhomogeneous dose prescription to the PTV encom-
passing 75% isodose line and treatment plans were nor-
malized to a mean GTV dose of 56.25 Gy in all plans and
treatment modalities. In total, 58 plans were generated
using 3D conformal radiotherapy (3DCRT) and volumet-
ric modulated arc therapy (VMAT). Details of planning
characteristics are described in Table 1. To evaluate po-
tential fractionation effects, two additional VMAT and
3DCRT fractionation schemes were analyzed (10 × 4.5 Gy
and 20 × 2.25 Gy), normalized to the same mean GTV
dose of 56.25 Gy.
Model description
Cumulative dose to CLs was calculated using a liver
segment specific DVH based convolution algorithm with
the following assumptions:
(1)About 7–9% of the arterial and 20–23% of the
intestinal bloodflow pass through the liver, which
equals to 27–32% of the total cardiac output [32, 33].
We used a value of 30% for our model.
(2)Regional hepatic blood flow is comparable in the
different liver segments [34].
(3)Mean hepatic blood flow velocity is 10 mm/s.
(4)Total body blood volume is 5 l.
(5)Cardiac output is 5 l/min, resulting in a circulation
time of 60 s for the total blood volume.
Fig. 1 Intrahepatic locations of the three virtual liver metastasis
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(6)Mean hepatic transition time is different in each
segment and based on proximity to arterial blood
supply and venous drainage. It was estimated using
the distance to the geometric center of each liver
segment from the arterial (hepatic artery) and
venous (portal vein) blood supply and venous
drainage (hepatic veins). Hepatic transition time per
segment varied from 7 to 23 s (see Additional file 1).
(7)Same “volumes” of the blood stream were
considered to be able to reenter the treatment field
between different arcs/beams and treatment
fractions, as the gantry rotation to the next arc or
beam takes longer than the average hepatic
transition and heart-to-heart circulation time.
(8)A dose of 0.5 Gy and greater was considered
effective in inactivating or killing circulating
lymphocytes. This dose cutoff has been chosen by
previous groups working on modelling CL irradiation
and is based on the intrinsic radiosensitivity of the
different lymphocyte subsets [23].
(9)The probability of reentering a specific liver segment
and thus treatment field, was calculated based on
the percentage of cardiac output and relative
volumes of the segments to generate a probability-
based DVH convolution algorithm. As the cardiac
output to the liver was defined as 30%, the probability
of reentering during each cycle the liver itself was
30%, while the probability of reentering a specific
segment varied from 2 to 22% (see Additional file 2).
We implemented an in-house developed model in
MATLAB (Mathworks) to estimate the dose delivered to
circulating lymphocytes based on the assumptions above.
Statistical analysis
The statistical analysis was performed in MATLAB,
graphs and illustrations were generated in GraphPad
Prism and Adobe Illustrator. The analysis considered
absolute and relative values of all treatment modalities
for each individual metastasis location, as well as mean
values of CL0.5, CL1.0, CL2.0, MLD, dose rate, number
of fractions and beam-on time.
Results
Mean liver dose (MLD) was mostly influenced by treat-
ment modality: lowest values were achieved by VMAT
followed by 3DCRT (Fig. 2a). In contrast, the proportion
of CLs receiving ≥0.5Gy (CL0.5) was mostly influenced
by beam-on time (BOT), which is associated with beam
energy and dose rate. Mean BOTs of 3DCRT were 57 s
(10MV FFF), 111 s (6MV FFF) and 253 s (6MV FF),
while total VMAT BOTs were 74 s (10MV FFF), 147 s
(6MV FFF) and 363 s (6MV FF).
Seven-field 3DCRT using 10MV FFF beams followed by
VMAT (10MV FFF) resulted in lowest mean CL0.5 values
of 16 and 19% (Fig. 2b). Treatment techniques using 6MV
or 6MV FFF beam energy, which resulted in longer BOTs,
showed substantially higher CL0.5 values with a mean of
24% or 31% for the 3DCRT and 24% or 25% for the
VMAT plans, respectively (Table 1). Additionally, metasta-
sis location influenced CL0.5, with a mean of 19% (11–
25%) for the apical, 19% (13–27%) for the basal and 31%
(24–41%) for the central location (Table 2).
We observed only a small fractionation effect for the
VMAT technique (Fig. 3a). For 10MV FFF beam (central
location) CL0.5 increased from 27% (3 fractions) over 30%
(10 fractions) to 32% (20 fractions). We did not observe a
fractionation effect for 3DCRT (see Additional file 3). An
increase in PTV volume in the central tumor location led
to a rapid increase of CL0.5 for all treatment modalities.
Once the volume reached about 100 cm3, this influence
reached a plateau and differences between modalities
scaled linearly with a further increase in PTV volume
(Fig. 3b). CL0.5 of VMAT (6MV FF) increased from 31%
(14 cm3) to 80% (65 cm3), 91% (113 cm3) and 98%
(268 cm3), while CL0.5 of VMAT (10MV FFF) only in-
creased from 27% (14 cm3) to 47% (65 cm3), 55%
(113 cm3) and 67% (268 cm3), respectively.
We also calculated the proportion of CLs receiving
≥1Gy (CL1.0), as well as CLs receiving ≥2.0Gy (CL2.0).
Table 1 Total beam-on time (BOT), mean liver dose (MLD) and proportion of circulating lymphocytes receiving ≥0.5Gy (CL0.5) by
treatment modality, beam energy and dose rate as a mean for all intrahepatic locations
1. Treatment modalities and mean MLD and CL0.5 of all locations
Treatment modality Beam energy Flattening filter Dose rate (MU/min) Fields / Arcs Total BOT MLD CL0.5
3DCRT 10 MV FFF 2400 7 57 s 4.3 Gy 15.9%
3DCRT 6 MV FFF 1400 7 111 s 4.3 Gy 23.6%
3DCRT 6 MV FF 600 7 253 s 4.3 Gy 30.9%
VMAT 10 MV FFF 2400 2 74 s 3.6 Gy 19.0%
VMAT 6 MV FFF 1400 3 147 s 3.6 Gy 23.6%
VMAT 6 MV FF 600 4 363 s 3.6 Gy 25.1%
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Higher dose rates with shorter BOTs led to increased
CL1.0 and CL2.0 values, while decreasing overall CL0.5
values and general low dose exposure of CLs (Fig. 4). In
larger PTV volumes, this effect was not present anymore
and higher dose rates decreased overall dose to CLs,
including CL0.5, CL1.0 and CL2.0 with only a slight
increase of doses greater than 3 Gy.
Discussion
Identifying predictive biomarkers for the response to im-
munotherapy is challenging and complex. Currently only
the expression of PD-L1 is widely used clinically but
there are several limitations and for many malignancies
PD-L1 expression alone might be insufficient for patient
selection [35, 36]. Peripheral blood markers have been
available for a long time and as previously stated: lym-
phopenia has been proposed as a prognostic factor for
overall survival in many cancer types [24–27] and
increased lymphocyte counts have also been associated
with increased response and survival in the setting of
immunotherapy [37–40]. It is also important to note
that tumor-associated antigens released by immunogenic
cell death of tumor cells are being generated during the
time of radiation and have a short half-life. The time-
frame around this antigen release might be most import-
ant for the induction of a systemic immune response.
Consequently, decreasing the detrimental effects of
radiotherapy on circulating lymphocytes might lead to a
further benefit in these scenarios.
We hypothesized that volume and location of the
treated liver metastasis as well as mean liver dose would
be relevant factors influencing the radiation dose deliv-
ered to circulating lymphocytes. Another assumption
was that volumetric arc therapy (e.g. VMAT) with its
increased spread of low dose has increased immunosup-
pressive effects and 3D–CRT might have advantages
with decreased low dose areas and shorter beam-on
times at the cost of decreased high-dose conformity.
We confirmed most of our assumptions but observed
that dose rate and treatment time had a stronger impact
on CL0.5 than MLD, which was mostly influenced by
treatment-modality. FFF beams in both 3DCRT and
VMAT drastically reduced beam-on-time resulting in
significantly lower CL0.5 values compared to lower
beam energies (e.g. 6MV-FF).
The Johns Hopkins and Memorial Sloan-Kettering
groups have shown that SBRT had a smaller effect than
conventional radiotherapy (CRT) on the total lymphocyte
count (TLC) in patients with unresectable pancreatic
cancer [41]. In general, patients with a higher post-
treatment TLC also showed a longer survival. The Oregon
Clinic group showed similar results with neoadjuvant che-
moradiation for borderline resectable and locally advanced
pancreatic cancer. SBRT with 30 Gy in 3 fractions over 1
week and concurrent Gemcitabine minimized treatment-
associated lymphopenia and reduced systemic loss of T
cells, which was common in patients receiving conven-
tional fractionated radiotherapy (CRT) with 50.4 Gy in 28
fractions over 5.5 weeks [42]. Additionally, the majority of
patients receiving CRT failed to normalize their TLC post-
treatment and it took up to 2 years in cases where TLC
normalization occurred. Most of the SBRT patients
Table 2 Mean liver dose (MLD) and proportion of circulating
lymphocytes receiving ≥0.5Gy (CL0.5) by intrahepatic locations
as a mean for all treatment modalities and beam energies
2. Dependence on tumor location
Tumor location MLD CL0.5
Apical 3.1 Gy 18.8%
Basal 3.4 Gy 19.0%
Central 5.3 Gy 31.3%
a b
Fig. 2 Mean liver dose (MLD, a) and proportion of circulating lymphocytes receiving ≥0.5Gy (CL0.5) by treatment modality as mean values with
SD for all intrahepatic locations (b)
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however where able to normalize their TLC within the
treatment period.
The Johns Hopkins group showed that the total dose
to circulating lymphocytes increases rapidly with the
number of fractions [23]. This effect is most likely based
on assumption (8) of lymphocyte re-entry, which was
also part of their analysis and considers possible reenter-
ing (sub-fractions) of the cells for every field (3D–CRT)
or arc (VMAT) into the treatment field. In our model,
we could not see a fractionation effect with 3DCRT and
noticed only a minor fractionation effect in the VMAT.
Differences to previous models may be the result of our
probability-based approach of each individual liver
segment and implementation of differing hepatic transi-
tion times compared to the single OAR approach of
Yovino et al. In contrast to the results of Yovino et al.,
BOT and dose rate seem to be very important factors.
We used higher dose rates with up to 2400 MU/min
without flattening filter, which might explain some of
the differences. With higher dose rates, less circulating
lymphocytes are irradiated and a smaller portion of lym-
phocytes receives a higher dose, as shown in Fig. 4.
In the studies of Wild and Crocenzi [41, 42], PTV size
was significantly larger for the conventionally fractionated
radiotherapy (89 cm3 SBRT vs. 345 cm3 CRT in the first
and approximately 150cm3 vs. 400cm3 in the second
study). Thus, we built a model based on equal PTV vol-
umes, while trying to optimize intra-fractional lymphocyte
sparing by choice of treatment modality, dose rate and
treatment time. PTV volume showed substantially larger
differences than fractionation in our analysis, suggesting
that the effect described in the studies above might be
volume rather than fractionation related, though this
would have to be confirmed in future in-vivo experiments.
PTV volume and treatment time seem to be the most
critical factors of lymphocyte sparing. In summary, im-
munosuppressive effects of SBRT might be minimized
by avoiding treatment of large metastases, a high num-
ber of fractions and especially long treatment times in
the setting of immunotherapy.
ba
Fig. 3 Effect of either 3 × 15 Gy, 10 × 4.5 Gy or 20 × 2.25 Gy fractionation on CLs (a) with VMAT 10MV FFF as treatment modality. 3DCRT did not show
a relevant fractionation effect (see Additional file 4). b. PTV volume dependent CL0.5 by treatment modality, based on either 14 cm3, 65 cm3, 114 cm3
or 268 cm3 PTV sizes in the central tumor metastasis
Fig. 4 CL0.0 to CL5.0 for VMAT 10MV FFF and 6MV FF in the central tumor location and either 14 cm3 or 268 cm3 PTV volume
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There are limitations to our model, including that the
value of CL0.5 is based on lymphocyte radio-sensitivity
which has been assessed in vitro via colony formation
assay [28] and in vivo data on dose-dependent activity
and function of circulating lymphocytes is scarce [43–46].
As seen in Fig. 4, we are however able to minimize not
only CL0.5 but also overall radiation exposure of CLs with
the right treatment modality. Additionally, radiation
sensitivity of lymphocytes is highly dependent on the
specific subset. Our model is of most relevance to
naïve T-cells, which are especially radiosensitive, com-
pared to other subsets such as memory cells [47–49].
In addition, overall survival may be associated with a
certain lymphocyte subset [50] and also be dependent
on other cell types, e.g. innate immune cells such as
neutrophils as discussed by Son et al. [51]. Regener-
ation and redistribution of lymphocytes, as well as
local/non-circulating lymphocytes were not considered
in our model and might influence the total amount of
irradiated lymphocytes. This could also be dependent
on tumor location and entity. However, this would
likely affect all treatment modalities and inclusion of
these factors would lead to a very complex model for
which several parameters are unknown. Additionally,
we do not know about the real impact of circulating
lymphocytes on the efficacy of immunotherapy and
immune-modulating antibodies may have additional
influences on lymphocytes, including alteration and
differentiation of subsets, as well as radiation sensitiv-
ity. However, the dependency of increased survival on
absolute lymphocyte count suggests that we may be
able to reduce detrimental radiation effects in this
regard. The development of models for clinical
decision-making is necessary for personalized treat-
ment strategies in the metastatic situation [52]. These
models should, however, be based on multiple bio-
logical and physiological parameters validated in-vivo
prior to clinical application [53].
Conclusion
A simulation-model has been established to estimate
and quantify potential immunosuppressive effects of
radiotherapy through inactivation of circulating lympho-
cytes. From a technical perspective, treatment delivery
time had the strongest impact on the proportion of
lymphocytes receiving ≥0.5Gy: best CL-sparing was
achieved with 10MV FFF 3DCRT followed by VMAT.
However, the clinical parameters metastasis location and
in particular metastasis volume had the strongest impact
on the immunosuppressive effects of radiotherapy. We
therefore believe that these results will be relevant in the
setting of combined radio-immunotherapy with potential
implications for immune-optimized treatment planning
in the future.
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